The histone methyltransferase (HMT) disruptor of telomeric silencing 1-like (DOT1L) has come to the forefront as a critical mediator of MLL-FP mediated leukemogenesis and has been shown to be required for the development, maintenance, and progression of MLL-R leukemias. Here, KMT2A is linked to leukemia.